Peroxiredoxin‐I is an autoimmunogenic tumor antigen in non‐small cell lung cancer

Authors:
  • YYYung Joon Yoo
    Yung Joon Yoo

Abstract
In eukaryotic cells, peroxiredoxins are both antioxidants and regulators of H2O2‐mediated signaling. We previously found that peroxiredoxin‐I (Prx‐I) was overexpressed in non‐small cell lung cancer (NSCLC) tissue. Since overexpressed protein can induce a humoral immune response, we examined whether serum from NSCLC patients exhibited immunoreactivity against Prx‐I using Western blotting. We found that 25 (47%) of 53 NSCLC patients tested had autoantibodies against Prx‐I in their sera, whereas such activity was detected in 4 (8%) sera from 50 healthy subjects. Prx‐I itself was detected in the sera from 18 (34%) of 53 NSCLC patients but in only 1 (2%) serum from 50 controls. Moreover, 17% of NSCLC sera were positive to both Prx‐I antibody and antigen but none in control sera. The data indicate both Prx‐I autoantibody and circulating antigen are potential biomarkers for use in serological diagnosis of NSCLC. Interestingly enough, we found that Prx‐I was secreted by lung adenocarcinoma cells (A549) but not by non‐cancer lung cells (BEAS 2B) or breast cancer cells (MCF7). This cell culture study suggests the possibility of Prx‐I secretion from NSCLC tumor tissues.

This publication has 32 references indexed in Scilit: